BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 12970754)

  • 1. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.
    Copland JA; Luxon BA; Ajani L; Maity T; Campagnaro E; Guo H; LeGrand SN; Tamboli P; Wood CG
    Oncogene; 2003 Sep; 22(39):8053-62. PubMed ID: 12970754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma.
    Ramp U; Jaquet K; Reinecke P; Nitsch T; Gabbert HE; Gerharz CD
    Lab Invest; 1997 May; 76(5):739-49. PubMed ID: 9166292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type.
    Ramp U; Jaquet K; Reinecke P; Schardt C; Friebe U; Nitsch T; Marx N; Gabbert HE; Gerharz CD
    J Urol; 1997 Jun; 157(6):2345-50. PubMed ID: 9146668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
    Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of TGFbeta signaling in skin carcinogenesis.
    Wang XJ
    Microsc Res Tech; 2001 Feb; 52(4):420-9. PubMed ID: 11170301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
    Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
    Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
    Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells.
    Koli KM; Arteaga CL
    Cancer Res; 1997 Mar; 57(5):970-7. PubMed ID: 9041203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene signatures of progression and metastasis in renal cell cancer.
    Jones J; Otu H; Spentzos D; Kolia S; Inan M; Beecken WD; Fellbaum C; Gu X; Joseph M; Pantuck AJ; Jonas D; Libermann TA
    Clin Cancer Res; 2005 Aug; 11(16):5730-9. PubMed ID: 16115910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas.
    Saini S; Liu J; Yamamura S; Majid S; Kawakami K; Hirata H; Dahiya R
    Cancer Res; 2009 Sep; 69(17):6815-22. PubMed ID: 19723665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
    Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
    Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
    Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
    Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
    Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
    Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
    Jöhrer K; Zelle-Rieser C; Perathoner A; Moser P; Hager M; Ramoner R; Gander H; Höltl L; Bartsch G; Greil R; Thurnher M
    Clin Cancer Res; 2005 Apr; 11(7):2459-65. PubMed ID: 15814620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.
    Mizutani Y; Nakanishi H; Yamamoto K; Li YN; Matsubara H; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    J Clin Oncol; 2005 Jan; 23(3):448-54. PubMed ID: 15572731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
    Wang J; Yang L; Yang J; Kuropatwinski K; Wang W; Liu XQ; Hauser J; Brattain MG
    Cancer Res; 2008 May; 68(9):3152-60. PubMed ID: 18451140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
    Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
    Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
    Kim IY; Lee DH; Lee DK; Kim BC; Kim HT; Leach FS; Linehan WM; Morton RA; Kim SJ
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6046-51. PubMed ID: 14676131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.